Uncategorized

Moderna stock nearly doubles as Merck-partnered mRNA cancer vaccine meets Phase 3 goal

Published

on

Melanoma was slower to recur in patients receiving Merck and Moderna’s mRNA vaccine with Keytruda, supporting use of the combination in adjuvant treatment. The partners plan to take the data to the FDA.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version